UY36965A - Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih - Google Patents

Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih

Info

Publication number
UY36965A
UY36965A UY0001036965A UY36965A UY36965A UY 36965 A UY36965 A UY 36965A UY 0001036965 A UY0001036965 A UY 0001036965A UY 36965 A UY36965 A UY 36965A UY 36965 A UY36965 A UY 36965A
Authority
UY
Uruguay
Prior art keywords
trivalent
prevention
treatment
specific
proteins
Prior art date
Application number
UY0001036965A
Other languages
English (en)
Inventor
Yang Zhi-Yong
J Nabel Gary
Ling Xu
Huawei Qui
Jochen Beninga
Jochen Kruip
Ercole Rao
Dirk Leuschner Wulf
Christian Beil
Christian Lange
Mark Connors
R Mascola John
A Koup Richard
Jinghe Huang
A Doria-Rose Nicole
Tongqing Zhou
D Kwong Peter
Do Kwon Young
Amarendra Pegu
Ronnie Wei
Original Assignee
Sanofi Sa
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Us Health filed Critical Sanofi Sa
Publication of UY36965A publication Critical patent/UY36965A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan proteínas de unión triespecíficas y/o trivalentes con cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas diana del VIH o uno o más receptores de células T, en donde un primer par de polipéptidos que forman la proteína de unión posee dominios variables duales con una orientación cruzada y donde un segundo par de polipéptidos posee un solo dominio variable. También se proporcionan métodos para preparar proteínas de unión triespecíficas y/o trivalentes y sus usos para el tratamiento y/o la prevención de VIH/SIDA.
UY0001036965A 2015-10-25 2016-10-25 Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih UY36965A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03

Publications (1)

Publication Number Publication Date
UY36965A true UY36965A (es) 2017-05-31

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036965A UY36965A (es) 2015-10-25 2016-10-25 Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih

Country Status (31)

Country Link
US (3) US20190054182A1 (es)
EP (2) EP3819310A1 (es)
JP (3) JP7169190B2 (es)
KR (1) KR20180063336A (es)
CN (4) CN117069855A (es)
AR (1) AR106466A1 (es)
AU (2) AU2016347058B2 (es)
BR (1) BR112018008011A2 (es)
CA (1) CA3002664A1 (es)
CL (1) CL2018001065A1 (es)
CO (1) CO2018005337A2 (es)
CR (1) CR20180288A (es)
DO (1) DOP2018000102A (es)
EA (1) EA201891028A1 (es)
ES (1) ES2894304T3 (es)
HK (1) HK1253385A1 (es)
HR (1) HRP20211528T1 (es)
HU (1) HUE056608T2 (es)
IL (2) IL301140A (es)
MA (1) MA42641A1 (es)
MX (2) MX2018005048A (es)
MY (1) MY192278A (es)
PE (1) PE20181167A1 (es)
PH (1) PH12018500873A1 (es)
PL (1) PL3365366T3 (es)
RS (1) RS62437B1 (es)
SG (1) SG11201803324VA (es)
SI (1) SI3365366T1 (es)
TW (2) TWI750139B (es)
UY (1) UY36965A (es)
WO (1) WO2017074878A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048770A2 (en) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
EP3110844B1 (en) * 2014-02-28 2020-02-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
AU2016347058B2 (en) * 2015-10-25 2023-11-09 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection
CN108884149B (zh) * 2015-11-03 2022-07-01 美国政府(由卫生和人类服务部的部长所代表) Hiv-1 gp41中和抗体及其用途
DK3443006T5 (da) 2016-04-13 2023-11-06 Sanofi Sa Trispecifikke og/eller trivalente bindingsproteiner
SG11201808911SA (en) * 2016-04-13 2018-11-29 Sanofi Sa Trispecific and/or trivalent binding proteins
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
CA3065328C (en) 2017-06-21 2023-08-15 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
CN111788225A (zh) * 2017-10-10 2020-10-16 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
CA3085351A1 (en) * 2017-12-21 2019-07-11 Aaron Diamond Aids Research Center Bispecific hiv-1-neutralizing antibodies
MX2020007444A (es) 2018-01-12 2020-09-14 Genzyme Corp Metodos para la cuantificacion de polipeptidos.
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
SG11202103478RA (en) * 2018-10-09 2021-05-28 Sanofi Sa Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
US20220025021A1 (en) * 2018-11-21 2022-01-27 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
EP3953388A1 (en) 2019-04-09 2022-02-16 Sanofi Trispecific binding proteins, methods, and uses thereof
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
CA3155356A1 (en) 2019-10-25 2021-04-29 Fateme TOUSI Methods for analyzing chain mispairing in multispecific binding proteins
WO2021203103A2 (en) * 2020-04-03 2021-10-07 Somasekar Seshagiri Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
AU2021333577A1 (en) * 2020-08-25 2023-03-30 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
TW202334204A (zh) * 2021-12-21 2023-09-01 美商莫德斯醫療公司 條件性活化之抗原結合多肽複合物及其使用方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
EP2706116A1 (en) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
EP1641826A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
CN103403026B (zh) 2009-09-25 2016-05-11 美国政府(由卫生和人类服务部的部长所代表) Hiv-1中和抗体及其用途
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
EP2638072A4 (en) 2010-11-12 2014-05-07 Univ Rockefeller FUSION PROTEINS FOR HIV THERAPY
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
PT2710033T (pt) * 2011-05-17 2021-03-11 Univ Rockefeller Anticorpos neutralizantes do vírus da imunodeficiência humana e métodos de utilização destes
RU2624046C2 (ru) 2011-11-07 2017-06-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Gp41-нейтрализующие антитела и их применение
CA2854806A1 (en) * 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
WO2013086533A1 (en) 2011-12-08 2013-06-13 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP2928924A4 (en) 2012-12-04 2016-07-13 Univ Maryland HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE
CA2889723A1 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
US20140213772A1 (en) 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN104936986B (zh) * 2013-02-26 2019-08-09 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
TW201446800A (zh) 2013-03-15 2014-12-16 Abbvie Inc 針對ＴＮＦα之雙特異性結合蛋白
WO2015017755A1 (en) 2013-08-02 2015-02-05 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
SG10201909806SA (en) 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
CA2996848C (en) 2014-09-04 2021-01-05 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
MA40801A1 (fr) 2015-01-23 2018-07-31 Sanofi Sa Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MX2022001187A (es) 2015-05-20 2023-01-04 Quantum Si Inc Método para determinar la secuencia de un ácido nucleico usando luminiscencia resuelta por tiempo.
US10654943B2 (en) 2015-06-02 2020-05-19 The Rockefeller University Tri-specific antibodies for HIV therapy
EA201890782A1 (ru) 2015-09-22 2018-09-28 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ перенацеливания t-клеток для лечения инфекции hiv
AU2016347058B2 (en) 2015-10-25 2023-11-09 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
EA202091898A1 (ru) 2015-12-15 2021-06-22 Джилид Сайэнс, Инк. Антитела, нейтрализующие вирус иммунодефицита человека
DK3443006T5 (da) 2016-04-13 2023-11-06 Sanofi Sa Trispecifikke og/eller trivalente bindingsproteiner
SG11201808911SA (en) 2016-04-13 2018-11-29 Sanofi Sa Trispecific and/or trivalent binding proteins
US20230242876A1 (en) 2016-12-30 2023-08-03 Shanghai Sinobio Biotech Co., Ltd. Bifunctional molecule and use thereof
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018183294A1 (en) 2017-03-27 2018-10-04 David Weiner Dna antibody constructs for use against hiv
CN111788225A (zh) 2017-10-10 2020-10-16 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
SG11202103478RA (en) 2018-10-09 2021-05-28 Sanofi Sa Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
AU2024200395A1 (en) 2024-04-11
DOP2018000102A (es) 2018-11-30
EP3365366B1 (en) 2021-07-14
CO2018005337A2 (es) 2018-07-10
CN109311966B (zh) 2023-03-10
SI3365366T1 (sl) 2022-02-28
CA3002664A1 (en) 2017-05-04
MX2022014631A (es) 2023-01-11
SG11201803324VA (en) 2018-05-30
US20190054182A1 (en) 2019-02-21
IL301140A (en) 2023-05-01
TWI750139B (zh) 2021-12-21
AU2016347058B2 (en) 2023-11-09
PE20181167A1 (es) 2018-07-19
JP7169190B2 (ja) 2022-11-10
PL3365366T3 (pl) 2022-01-31
WO2017074878A1 (en) 2017-05-04
AR106466A1 (es) 2018-01-17
IL258822B2 (en) 2023-08-01
US11779651B2 (en) 2023-10-10
HUE056608T2 (hu) 2022-02-28
MA42641A1 (fr) 2019-03-29
CL2018001065A1 (es) 2018-11-23
JP2018537966A (ja) 2018-12-27
HK1253385A1 (zh) 2019-06-14
KR20180063336A (ko) 2018-06-11
EA201891028A1 (ru) 2019-02-28
JP2023085476A (ja) 2023-06-20
BR112018008011A2 (pt) 2018-10-30
JP2021072847A (ja) 2021-05-13
HRP20211528T1 (hr) 2021-12-24
IL258822A (en) 2018-06-28
CN116675776A (zh) 2023-09-01
TW201730210A (zh) 2017-09-01
EP3365366A1 (en) 2018-08-29
JP7328267B2 (ja) 2023-08-16
CR20180288A (es) 2018-09-11
TW202219064A (zh) 2022-05-16
IL258822B1 (en) 2023-04-01
US11129905B2 (en) 2021-09-28
CN116789841A (zh) 2023-09-22
ES2894304T3 (es) 2022-02-14
RS62437B1 (sr) 2021-11-30
PH12018500873A1 (en) 2018-11-12
US20220226495A1 (en) 2022-07-21
MX2018005048A (es) 2018-09-06
CN117069855A (zh) 2023-11-17
AU2016347058A1 (en) 2018-06-14
CN109311966A (zh) 2019-02-05
MY192278A (en) 2022-08-16
US20200054765A1 (en) 2020-02-20
EP3819310A1 (en) 2021-05-12
WO2017074878A8 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
UY36965A (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
CO2018012107A2 (es) Proteínas de unión triespecíficas y/o trivalentes
BR112018067458A2 (pt) anticorpos para tigit
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
PE20170767A1 (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
CO2018013104A2 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
CL2018001565A1 (es) Inmunoglobulinas conjugadas con lisina c-terminal
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
CO2017011583A2 (es) Polipéptidos dirigidos a la fusión de vih
EA201890739A1 (ru) Анти-s100a8 для лечения лейкемии
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
ECSP18039758A (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение
AR118602A1 (es) Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih
ECSP18084491A (es) Proteínas de unión triespecíficas y/o trivalentes
AR108210A1 (es) Proteínas de unión triespecíficas y/o trivalentes
EA202191078A2 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
EA201990505A1 (ru) Анти-tigit антитела, анти-pvrig антитела и их комбинации

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221212